{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:44:00Z","timestamp":1780458240068,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84574-y","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T03:15:41Z","timestamp":1735874141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["DGCR2 targeting affibody molecules for delivery of drugs and imaging reagents to human beta cells"],"prefix":"10.1038","volume":"15","author":[{"given":"Pierre","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Vasylovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Invast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Korsgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00e5hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"L\u00f6fblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"84574_CR1","doi-asserted-by":"publisher","unstructured":"Grattoni, A. et al. Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead. Nat. Rev. Endocrinol. Published Online September. 3 https:\/\/doi.org\/10.1038\/s41574-024-01029-0 (2024).","DOI":"10.1038\/s41574-024-01029-0"},{"issue":"1","key":"84574_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12656","volume":"183","author":"MG von Herrath","year":"2016","unstructured":"von Herrath, M. G., Korsgren, O. & Atkinson, M. A. Factors impeding the discovery of an intervention-based treatment for type 1 diabetes. Clin. Exp. Immunol. 183 (1), 1\u20137 (2016).","journal-title":"Clin. Exp. Immunol."},{"issue":"12","key":"84574_CR3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3390\/biomedicines9121824","volume":"9","author":"P Cheung","year":"2021","unstructured":"Cheung, P. & Eriksson, O. The current state of beta-cell-mass PET imaging for diabetes research and therapies. Biomedicines 9 (12), 1824 (2021).","journal-title":"Biomedicines"},{"issue":"7","key":"84574_CR4","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s00125-016-3959-7","volume":"59","author":"O Eriksson","year":"2016","unstructured":"Eriksson, O. et al. In vivo imaging of beta cells with radiotracers: State of the art, prospects and recommendations for development and use. Diabetologia [Internet]. 59 (7), 1340\u20131349 (2016).","journal-title":"Diabetologia [Internet]"},{"issue":"9","key":"84574_CR5","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1016\/j.jprot.2012.03.008","volume":"75","author":"C Lindskog","year":"2012","unstructured":"Lindskog, C. et al. Novel pancreatic beta cell-specific proteins: Antibody-based proteomics for identification of new biomarker candidates. J. Proteom. 75 (9), 2611\u20132620 (2012).","journal-title":"J. Proteom."},{"issue":"6","key":"84574_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.stemcr.2015.10.013","volume":"5","author":"JE Bruin","year":"2015","unstructured":"Bruin, J. E. et al. Accelerated maturation of human stem cell-derived pancreatic progenitor cells into insulin-secreting cells in immunodeficient rats relative to mice. Stem Cell. Rep. 5 (6), 1081\u20131096 (2015).","journal-title":"Stem Cell. Rep."},{"issue":"1","key":"84574_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13550-023-01057-3","volume":"13","author":"P Cheung","year":"2023","unstructured":"Cheung, P. et al. Preclinical evaluation of affibody molecule for PET imaging of human pancreatic islets derived from stem cells. EJNMMI Res. 13 (1), 107 (2023).","journal-title":"EJNMMI Res."},{"key":"84574_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fcell.2020.00202","volume":"8","author":"T Tesovnik","year":"2020","unstructured":"Tesovnik, T. et al. Extracellular vesicles derived human-miRNAs modulate the immune system in type 1 diabetes. Front. Cell. Dev. Biol. 8, 202 (2020).","journal-title":"Front. Cell. Dev. Biol."},{"issue":"2","key":"84574_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/gim.2016.98","volume":"19","author":"SL Voll","year":"2017","unstructured":"Voll, S. L. et al. Obesity in adults with 22q11.2 deletion syndrome. Genet. Med. 19 (2), 204\u2013208 (2017).","journal-title":"Genet. Med."},{"key":"84574_CR10","doi-asserted-by":"publisher","first-page":"100528","DOI":"10.1016\/j.eclinm.2020.100528","volume":"26","author":"L Van","year":"2020","unstructured":"Van, L. et al. 22q11.2 microdeletion and increased risk for type 2 diabetes. EClinicalMedicine 26, 100528 (2020).","journal-title":"EClinicalMedicine"},{"issue":"3","key":"84574_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/JME-20-0082","volume":"65","author":"DW Scoville","year":"2020","unstructured":"Scoville, D. W., Gruzdev, A. & Jetten, A. M. Identification of a novel lncRNA (G3R1) regulated by GLIS3 in pancreatic \u03b2-cells. J. Mol. Endocrinol. 65 (3), 59\u201367 (2020).","journal-title":"J. Mol. Endocrinol."},{"issue":"2","key":"84574_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ng.2870","volume":"46","author":"L Pasquali","year":"2014","unstructured":"Pasquali, L. et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat. Genet. 46 (2), 136\u2013143 (2014).","journal-title":"Nat. Genet."},{"issue":"4","key":"84574_CR13","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2967\/jnumed.116.177659","volume":"58","author":"AT Mayer","year":"2017","unstructured":"Mayer, A. T. et al. Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging. J. Nucl. Med. 58 (4), 538\u2013546 (2017).","journal-title":"J. Nucl. Med."},{"issue":"8","key":"84574_CR14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","volume":"35","author":"S St\u00e5hl","year":"2017","unstructured":"St\u00e5hl, S. et al. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 35 (8), 691\u2013712 (2017).","journal-title":"Trends Biotechnol."},{"key":"84574_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-1-61779-921-1_7","volume":"899","author":"J Feldwisch","year":"2012","unstructured":"Feldwisch, J. & Tolmachev, V. Engineering of affibody molecules for therapy and diagnostics. Methods Mol. Biol. 899, 103\u2013126 (2012).","journal-title":"Methods Mol. Biol."},{"issue":"10","key":"84574_CR16","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1158\/1535-7163.MCT-09-0195","volume":"8","author":"MM Schmidt","year":"2009","unstructured":"Schmidt, M. M. & Wittrup, K. D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer Ther. 8 (10), 2861\u20132871 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"84574_CR17","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05623345?term=izokibep&rank=2, accessed 09-OCT-2024."},{"issue":"7","key":"84574_CR18","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41587-022-01219-z","volume":"40","author":"D Balboa","year":"2022","unstructured":"Balboa, D. et al. Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat. Biotechnol. 40 (7), 1042\u20131055 (2022).","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"84574_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/biot.201800359","volume":"14","author":"KG Andersson","year":"2019","unstructured":"Andersson, K. G., Persson, J., St\u00e5hl, S. & L\u00f6fblom, J. Autotransporter-mediated display of a na\u00efve affibody library on the outer membrane of Escherichia coli. Biotechnol. J. 14 (4), 1\u20138 (2019).","journal-title":"Biotechnol. J."},{"issue":"1","key":"84574_CR20","doi-asserted-by":"publisher","first-page":"19151","DOI":"10.1038\/s41598-021-97694-6","volume":"11","author":"J Persson","year":"2021","unstructured":"Persson, J. et al. Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69. Sci. Rep. 11 (1), 19151 (2021).","journal-title":"Sci. Rep."},{"issue":"1","key":"84574_CR21","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1038\/s41467-022-29377-3","volume":"13","author":"D Van Simaeys","year":"2022","unstructured":"Van Simaeys, D. et al. RNA aptamers specific for transmembrane p24 trafficking protein 6 and Clusterin for the targeted delivery of imaging reagents and RNA therapeutics to human \u03b2 cells. Nat. Commun. 13 (1), 1815 (2022).","journal-title":"Nat. Commun."},{"issue":"2","key":"84574_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2337\/db14-0656","volume":"64","author":"PO Carlsson","year":"2015","unstructured":"Carlsson, P. O., Schwarcz, E., Korsgren, O. & Le Blanc, K. Preserved \u03b2-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 64 (2), 587\u2013592. https:\/\/doi.org\/10.2337\/db14-0656 (2015).","journal-title":"Diabetes"},{"key":"84574_CR23","doi-asserted-by":"publisher","unstructured":"Witwer, K. W. et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J. Extracell. Vesicles. 8 (1). https:\/\/doi.org\/10.1080\/20013078.2019.1609206 (2019).","DOI":"10.1080\/20013078.2019.1609206"},{"issue":"3","key":"84574_CR24","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.3390\/ma3031928","volume":"3","author":"R Solaro","year":"2010","unstructured":"Solaro, R., Chiellini, F. & Battisti, A. Targeted delivery of protein drugs by nanocarriers. Materials 3 (3), 1928\u20131980 (2010).","journal-title":"Materials"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84574-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84574-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84574-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:48:34Z","timestamp":1744116514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84574-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84574"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84574-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"O.E. is an employee of Antaros Tracer. O.E. and O.K. are minority shareholders of Antaros Tracer AB, which hold patents related to DGCR2 binding peptides. Otherwise, the authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the performed procedures were in accordance with the ARRIVE guidelines for animal research. The animal experiments were ethically reviewed, authorized by the Animal Ethics Committee of the Swedish Animal Welfare Agency and carried out in accordance with the European Directive 2010\/63\/EEC and the institutional guidelines at Uppsala University (UFV 2007\/724).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"417"}}